What HOPE Therapeutics does

HOPE Therapeutics is a wholly-owned subsidiary of NRx Pharmaceuticals (NASDAQ: NRXP) that operates a network of interventional psychiatry clinics in Florida delivering neuroplastic therapies for treatment-resistant mental health conditions, primarily major depressive disorder, PTSD, anxiety, OCD, and acute suicidal ideation. The company's clinical model centers on three FDA-cleared or approved modalities: Transcranial Magnetic Stimulation (TMS) using the AI-guided Zeta Surgical navigation system for sub-millimetric precision targeting, intravenous ketamine infusion therapy, and SPRAVATO (esketamine) nasal spray administration. These are complemented by ketamine-assisted psychotherapy, EMDR, medication management, and psychotherapy services, with insurance-based billing across major commercial payers plus Medicare.

The company's technology stack includes the first commercial deployment of Zeta Surgical's FDA-cleared AI-powered TMS navigation system (sub-millimetric accuracy, <2-minute setup without fiducial markers) and the Emobot EMOCARE smartphone-based passive depression monitoring platform (90% concordance with clinician MADRS ratings). HOPE is building a vertically integrated model that combines clinical delivery, AI-guided device technology, remote monitoring, and clinical trial site operations for the parent company's drug development pipeline (including the SPARC-TMS trial combining NRX-101 with TMS).

HOPE generates revenue on a per-session basis through insurance reimbursement for qualifying patients, with the typical payer mix requiring documented failure of two or more antidepressant trials for TMS/SPRAVATO coverage. The company has grown from zero to five Florida clinic locations between September 2025 and Q1 2026 through acquisition (Dura Medical) and organic build-out, with additional acquisition targets (Neurospa TMS) in the pipeline. Initial clinic revenue began in Q1 2026, marking the transition from deployment to active patient care. The business is operationally constrained to Florida currently, with no disclosed geographic expansion plans beyond the existing footprint.

Name

HOPE Therapeutics

Legal name

Hope Therapeutics Inc.

Website

https://hopetherapeutics.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

HOPE Therapeutics operates a network of five interventional psychiatry clinics in Florida delivering FDA-cleared neuroplastic therapies (TMS, IV ketamine, SPRAVATO) for treatment-resistant depression, PTSD, anxiety, and OCD, serving individual patients via insurance reimbursement.

Ownership category

akta.pro rank

Product category

Interventional Psychiatry Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330)

SIC

Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)

akta.pro secondary industries

Psychiatry & Medication Management Platforms (HLALAEAB), Outpatient Mental Health & Counseling Clinics (HLAFABAC), Crisis Support, Suicide Prevention & Acute Behavioral Triage Platforms (HLALAEAI), Mental Health Counseling & Psychotherapy Services (EDALAFAB)

Keywords

• Interventional psychiatry
• Neuroplastic therapy services
• TMS treatment clinics
• Ketamine infusion therapy
• Treatment-resistant depression care

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Treatment Services: Revenue generated from administering neuroplastic therapies including IV Ketamine infusions, SPRAVATO nasal spray treatments, and TMS sessions. Treatments are typically covered by insurance for qualifying patients with treatment-resistant depression or major depressive disorder with suicidal ideation. Initial revenue generation began Q1 2026 from five interventional psychiatry clinics.
2. Psychiatric Medication Management: Ongoing psychiatric medication management services including evaluation, prescription management, and monitoring for patients receiving neuroplastic treatments or standalone psychiatric care.
3. Psychotherapy Services: Individual and group psychotherapy sessions provided by licensed mental health counselors, therapists, and psychiatric nurse practitioners, billed per session or covered by insurance.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

HOPE Therapeutics operates a network of interventional psychiatry clinics in Florida providing neuroplastic therapies including Transcranial Magnetic Stimulation (TMS), IV Ketamine, and SPRAVATO (esketamine) for treatment-resistant depression, anxiety, PTSD, and other mental health conditions. The clinics integrate FDA-cleared AI-guided TMS navigation technology with comprehensive psychiatric care including medication management, psychotherapy, EMDR, and telehealth services. Treatments are covered by most major insurance plans for qualifying patients.

Product overview

HOPE Therapeutics operates a network of interventional psychiatry clinics across Florida (Fort Myers, Naples, Sarasota, West Palm Beach) offering neuroplastic therapies for treatment-resistant mental health conditions. The core treatment portfolio centers on three FDA-cleared/approved neuroplastic therapies: TMS Therapy (using Zeta Surgical's AI-guided navigation system for sub-millimetric precision), IV Ketamine and SPRAVATO (esketamine) for rapid-acting relief, and Ketamine-Assisted Psychotherapy. These are complemented by foundational services including psychotherapy, talk therapy, EMDR therapy, medication management, telehealth services, and specialized programs like the Hope Accelerated Care protocol and Emobot's AI-powered depression monitoring platform. The treatment approach integrates medical interventions with psychotherapy to leverage neuroplasticity windows for lasting psychological change.

Differentiator

Problem solved

Functional benefit

Brands

• HOPE Accelerated Care: Cutting-edge, rapid-relief treatment options for patients offering IV Ketamine Therapy and Accelerated TMS Therapy at the West Palm Beach location.

Products and services

• TMS Therapy FDA-cleared, non-invasive Transcranial Magnetic Stimulation using targeted magnetic pulses to stimulate underactive brain regions associated with mood regulation. HOPE uses the Zeta Surgical AI-guided TMS Navigation System for sub-millimetric precision targeting. Indicated for patients with treatment-resistant depression and OCD who have not responded to medication.
• IV Ketamine Therapy Intravenous ketamine therapy delivering fast-acting relief for treatment-resistant depression, anxiety, PTSD, and OCD through infusion in a supervised clinical setting, often producing noticeable improvement within hours or days rather than weeks.
• SPRAVATO Treatment FDA-approved esketamine nasal spray for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Administered in-clinic alongside an oral antidepressant, it targets the brain's glutamate system for rapid relief. Available only at certified SPRAVATO REMS treatment centers.
• Ketamine-Assisted Psychotherapy Ketamine-Assisted Psychotherapy (KAP) pairs the neurological effects of ketamine with structured therapeutic support, where a trained therapist guides patients through the experience to translate heightened brain openness into lasting psychological healing.
• Intranasal Ketamine (Compounded) Compounded intranasal ketamine treatment option available at HOPE Therapeutics clinics for depression and related conditions as an alternative delivery method to IV infusion.
• Psychotherapy Evidence-based psychotherapy provided as a standalone treatment or integrated with neuroplastic therapies (TMS, ketamine, SPRAVATO) to address psychological patterns, trauma histories, and develop coping skills during periods of heightened neuroplasticity.
• Talk Therapy Evidence-based psychotherapy designed to work alongside neuroplastic treatments, leveraging the therapeutic window created by TMS, ketamine, or SPRAVATO to produce greater and more durable psychological change.
• EMDR Therapy Eye Movement Desensitization and Reprocessing (EMDR) therapy helps the brain reprocess traumatic or distressing memories using bilateral stimulation, recognized by WHO and APA as a first-line treatment for PTSD.
• Telehealth Services HIPAA-compliant video or phone mental health consultations enabling patients to access therapy, psychiatric evaluations, and medication management remotely across Florida.
• Medication Management Psychiatric medication management including careful medication selection, consistent monitoring of effectiveness and tolerability, dosage refinements, and coordination with other treatments.
• Smoking Cessation Program TMS-based treatment program designed to help reduce cravings and addictive behaviors by modulating the brain's reward pathways, supporting patients' journey to quit smoking.
• Hope Accelerated Care Specialized rapid-relief treatment program at the West Palm Beach location offering IV Ketamine Therapy and Accelerated TMS Therapy for treatment-resistant depression, anxiety, PTSD, and other conditions.

Quantifiable outcome

• 69% of treatment-resistant depression patients experience significant symptom improvement with TMS therapy
• +4 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Zeta SurgicalcoreTechnology or Integration · 1 April 2026Strategic partnership for deployment of Zeta Surgical's FDA-cleared Zeta TMS Navigation System at HOPE Therapeutics clinics. The AI-powered navigation system provides sub-millimetric image guidance for transcranial magnetic stimulation procedures, representing the first commercial deployment of the technology. HOPE became the first commercial site to deploy the system at its West Palm Beach, Florida clinic, with subsequent deployment at Sarasota location.
• Emobot HealthcoreTechnology or Integration · 30 March 2026Strategic partnership to deploy Emobot's EMOCARE AI-powered Depression Thermometer across HOPE Therapeutics' interventional psychiatry clinic network. The smartphone-based passive monitoring platform monitors depression and related conditions to help detect early relapse and improve treatment outcomes, with clinical validation showing 90% concordance with clinician-rated assessments.
• Ampa HealthminorStrategic or Co-development Partner · 1 November 2025Partnership with Ampa Health to offer the ONE-D (One Day) depression treatment protocol, combining TMS with D-cycloserine and lisdexamfetamine for treatment-resistant depression. HOPE Therapeutics announced first-in-Florida initiation of this protocol using an FDA-cleared device, aiming to shorten depression treatment courses significantly.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Mindbloom: Direct-to-consumer at-home ketamine therapy provider operating in multiple states. Comparable in target patient segment (treatment-resistant depression) and ketamine modality, though via telehealth/at-home model rather than clinic-based infusion.
• Compass Pathways: Public (NASDAQ: CMPS) clinical-stage psychedelic therapy company developing psilocybin treatment for treatment-resistant depression. Comparable as an interventional psychiatry innovator targeting the same patient population, though focused on drug development rather than clinic delivery.

Direct peers

• Apollo TMS: Regional TMS clinic network in Texas offering Transcranial Magnetic Stimulation for depression, OCD, and PTSD. Directly comparable as a multi-site interventional psychiatry operator with insurance-based reimbursement.
• Success TMS: Multi-state TMS clinic network offering transcranial magnetic stimulation for depression, anxiety, OCD, and PTSD. Comparable as a regional roll-up of interventional psychiatry practices with insurance-based service delivery.
• DelRAY Recovery Center: Florida-based behavioral health provider offering TMS, ketamine therapy, and outpatient mental health services in Delray Beach. Comparable geographically (Florida overlap) and in interventional psychiatry modality mix.
• Mindpath Health: Multi-state outpatient mental health provider offering psychiatry, therapy, and interventional treatments including TMS and ketamine. Comparable in offering combination of medication management, psychotherapy, and TMS/ketamine under integrated care teams.
• Field Trip Health (Stella): Operator of ketamine-assisted psychotherapy clinics across the US and Canada for treatment-resistant depression and PTSD. Directly comparable in modality mix (IV ketamine, KAP, TMS at select sites) and patient segments, though pursuing at-home ketamine pivots.
• Greenbrook TMS NeuroHealth Centers: Public (formerly TSX: GTMS) multi-state operator of TMS-focused clinics for treatment-resistant depression and OCD. Directly comparable as the closest publicly-traded pure-play in interventional psychiatry, though at much larger scale (~100+ clinics pre-acquisition).

Broad incumbents

• Sage Therapeutics: Public (NASDAQ: SAGE) CNS biopharmaceutical company developing zuranolone (Zurzuvae) for postpartum depression and MDD. Comparable as a parent-pharma parallel to NRx Pharmaceuticals backing HOPE; both leverage pharma drug pipelines with clinical delivery / interventional psychiatry synergies.
• NeuroStar Advanced Therapy (Neuronetics): Public (NASDAQ: STIM) manufacturer of the leading TMS device (NeuroStar) and operator of affiliated treatment centers. Comparable as the dominant commercial TMS platform; HOPE's Zeta Surgical partnership represents a potential competitive response to Neuronetics' integrated device-plus-clinic model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/HOPETherapeutx
• LinkedInlinkedin.com/company/hopetherapeutics
• Instagraminstagram.com/hopetherapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HOPE Therapeutics